# Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

> **NCT00449072** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 299 (actual)

## Conditions studied

- Rhinitis, Allergic, Perennial

## Interventions

- **OTHER:** Placebo
- **OTHER:** Placebo
- **DRUG:** TAA-AQ, Nasacort® AQ
- **DRUG:** Claritin®

## Key facts

- **NCT ID:** NCT00449072
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2012-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00449072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00449072, "Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00449072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*